

Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer

A Kenneth MacLeod¹, Lourdes Acosta-Jimenez¹, Philip J Coates^{1,4}, Michael McMahon¹, Frank A Carey², Tadashi Honda³, John D Hayes¹, Colin J Henderson¹ and C Roland Wolf¹

¹Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK; ²Department of Pathology and Neuroscience, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK and ³Department of Chemistry and Institute of Chemical Biology and Drug Discovery, Stony Brook University, New York, NY 11794-3400, USA

Correction to: *British Journal of Cancer* (2016) **115**, 1530–1539. doi:10.1038/bjc.2016.363; published online 8 November 2016

After publication of the above paper in the *British Journal of Cancer*, the authors recognised that John D Hayes had been

omitted from the original author list. The authors would like to apologise for this mistake. The revised author list and affiliations appear above.

⁴Current address: RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic. published online 21 March 2017